Bristol Myers Squibb announced today that CheckMate -743, a pivotal phase 3 trial evaluating Opdivo (nivolumab) in combination with Yervoy (ipilimumab) in previously untreated malignant pleural mesothelioma, met its primary endpoint of overall…
Bristol Myers Squibb announced today that CheckMate -743, a pivotal phase 3 trial evaluating Opdivo (nivolumab) in combination with Yervoy (ipilimumab) in previously untreated malignant pleural mesothelioma, met its primary endpoint of overall…